Precigen to Announce Fourth Quarter and Full Year 2023 Financial Results on March 19thPRNewsWire • 03/05/24
Precigen to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences ConferencePRNewsWire • 02/06/24
Precigen Receives Orphan Drug Designation for PRGN-2012 for the Treatment of Recurrent Respiratory Papillomatosis from the European CommissionPRNewsWire • 01/16/24
Precigen Highlights Pipeline Updates to be Presented at the 42nd Annual J.P. Morgan Healthcare ConferencePRNewsWire • 01/08/24
Precigen Reports Third Quarter 2023 Financial Results and Progress of Clinical ProgramsPRNewsWire • 11/09/23
Precigen Reports Second Quarter and First Half 2023 Financial Results and Provides Update on Portfolio Prioritization and Capital Allocation Strategies to Extend Projected Cash Runway into 2025PRNewsWire • 08/09/23
Precigen Announces FDA Confirmation that the Ongoing Phase 1/2 Study of PRGN-2012 AdenoVerse Immunotherapy Will Serve as the Pivotal Study to Support Accelerated ApprovalPRNewsWire • 08/09/23
Precigen to Announce Second Quarter and First Half 2023 Financial Results on August 9thPRNewsWire • 08/03/23
Precigen Receives Breakthrough Therapy Designation for PRGN-2012 AdenoVerse™ Immunotherapy for the Treatment of Recurrent Respiratory PapillomatosisPRNewsWire • 06/20/23
Precigen Announces Positive Phase 1 Data for PRGN-3005 Autologous UltraCAR-T® Cells Manufactured Overnight for Infusion Next Day to Advanced Stage Platinum Resistant Ovarian Cancer PatientsPRNewsWire • 06/05/23
Precigen Announces Positive Phase 1 Data for Off-the-Shelf PRGN-2009 AdenoVerse™ Immunotherapy Alone and in Combination with an Investigational Checkpoint Inhibitor in Patients with Recurrent/Metastatic HPV-associated CancersPRNewsWire • 06/03/23
Precigen Receives FDA Clearance of IND to Initiate Phase 2 Study of PRGN-2009 Off-the-Shelf AdenoVerse Immunotherapy in Combination with Pembrolizumab to Treat Patients with Recurrent or Metastatic Cervical CancerPRNewsWire • 05/31/23